- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03937895
Recruitment Status Recruiting
First Posted May 6, 2019
Last update posted January 18, 2020
The term of biliary tract cancer (BTC) or cholangiocarcinoma refers to all tumors that arise from the biliary tract or the biliary drainage system, including the gallbladder. According to the data from National Cancer Information Center in 2016, annual incidence of the cancer in Korea is 6,685 (13.1 per 100,000 population) which corresponds to about 2.9% of all cancers. BTC is one of the most prognostic cancer with less than 30% of 5-year survival rate and the case with long-term survival can be possibly done with early detection of the cancer. However, most of BTC is found in advanced stages due to the difficulty of early detection, resulting in that the 5-year survival rate of the advanced BTC becomes less than 3%. More than 50% of the patients depends on Gemcitabine based chemotherapy but response rate of the chemotherapy remains around 30%. Thus, improving the survival rate with the standard chemotherapy is very limited and furthermore selection of second-line therapy is not easy. For this reason, development of an alternative therapeutic agent is urgently required. NK (natural killer) cells are important cytotoxic innate immune cells that are involved in the elimination of cancer cells. Two main NK cell subsets have been defined on the basis of CD56 and CD16 expression: CD56^brightCD16− NK subset produces abundant cytokines including interferon-γ (IFN-γ) and tumor necrosis factor-α, whereas CD56^dimCD16+ NK subpopulation has high cytolytic activity and releases the granules containing perforin and granzymes. Various clinical studies have been conducted to treat cancers using NK cells worldwide including Korea and therapeutic clinical results are shown for various cancers. The clinical application of NK cells is carried out by culturing and activating the NK cells isolated from blood of either patient (autologous) or blood donor (allogeneic). Recently, NK cell therapy for cholangiocarcinoma has been successfully done (NCT03358849) with allogeneic NK cell, showing safety and potential efficacy. Like T cells, a recent study with digestive cancer has shown that NK cells also express PD-1, especially with more number of PD-1 in cancer patients than in healthy individuals, suggesting that blocking PD-1 can be used as a potential strategy to increase the anticancer activity of NK cells. Therefore, combined therapy with the immune-check point such as pembrolizumab can be useful in elevating the anticancer activity of NK cells.
|Experimental: Experimental: single arm
Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to *cycle 3, Phase 2a: up to cycle 9) Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle. Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period.
Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell)
In 120 mL, 3x10^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
Drug: Pembrolizumab Injection [Keytruda]
Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
Patients who received a histopathological or cytologic diagnosis of nonresectable, advanced
biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder
cancer) and patients with refractory disease after chemotherapy and/or patients who have
difficulty with chemotherapy due to side effects of chemotherapy.
1. A person who receives an explanation from the trial manager about the purpose,
contents, and characteristics of the Investigational products for the clinical trial
and is signed by the person, guardian or legal representative in the written informed
2. Be ≥19 years of age on day of signing informed consent.
3. Histopathological or cytologic diagnosis of advanced adenocarcinoma of the biliary
4. Have a performance status of ≤2 on the ECOG Performance Scale.
5. Patients who survival period is expected to be at least 3 months.
6. Patients who meet the following conditions:
- ANC(Absolute Neutrophil Count) ≥ 1,500/μL
- Hemoglobin≥ 10 g/dL
- Platelet> 100,000/μL
- Serum BUN & Creatinine ≤ 1.5 x upper limit of normal (ULN)
- AST & ALT ≤ 2.5 x upper limit of normal (ULN)
- Bilirubin ≤ 3mg/L
7. Patients who agreed to the allogeneic natural killer cells therapy separated from the
family of the patient or healthy donor's blood.
8. Patients have a negative serum or urine pregnancy test (HCG, human chorionic
gonadotropin) within 72 hours prior to receiving the first dose of study medication
and agreed to use 2 methods of contraception. The period of contraception is up to 6
months after the last administration of Pembrolizumab.
9. Patients who meet one or more of the following conditions.
- Patients have at least 1% Combined Positive Score (*CPS) PD-L1 expression
detected on the tumor, as determined by **immunohistochemistry performed by a
*CPS = (number of PD-L1 positive tumor cells, lymphocytes, macrophage)/ (total
number of viable tumor cells) X 100
**immunohistochemistry: IHC 22C3 pharmDx test
- Patients who have a positive *MSI-H or **dMMR test.
- MSI-high positive tumors analyzed by PCR.
- dMMR positive tumors analyzed by immunohistochemical staining .
- *MSI-H was measured by PCR, and positive finding when two or more
unstable markers were detected in PCR for 5 microsatellite markers.
- **dMMR is analyzed by immunohistochemical staining and positive when
the discovery of one or more genes in MLH1, MSH2, MSH6 and PMS2
staining is lost.
1. Patients who have previous history of Immune deficiency or autoimmune disease that can
be aggravated by immunotherapy(for example: Rheumatoid arthritis, systemic lupus
erythematosus, vasculitis, multiple sclerosis, Crohn's disease, ulcerative colitis,
adolescent-developed insulin-dependent diabetes mellitus).
2. Diagnosis of immunodeficiency or is receiving systemic steroid therapy.
3. Have with pneumonia, colitis, hepatitis, nephritis, endocrine disorders(for example:
Pituitary gland, thyroid dysfunction, Type 1 diabetes, etc.) associated with
4. Other malignant tumors within 5 years before the study enrollment.
5. Previous history of anti-angiogenic agent treatment before the study enrollment.
6. Received chemotherapy not less than 4 weeks old before the first administration of
7. Apparent myocardial infarction or uncontrolled arterial hypertension.
8. Serious allergic history.
9. Serious mental illness.
10. Female who are pregnant, breastfeeding or intending to become pregnant during the
11. A person who participated in another clinical trial within 4 weeks prior to the start
of the study(based on the date of signing the informed consent.).
12. Previously administrated Pembrolizumab and other anti-PD-1/PD-L1 agent.
13. Previously administrated natural killer cell.
14. Patients who did not resolve the adverse event of the drug administered 4 weeks prior
15. Previous history of active central nervous system (CNS) metastasis and/or
16. Previous history of non-infectious pneumonia.
17. Previous history of Has an active infection requiring systemic therapy.
18. Previous historyof Human Immunodeficiency Virus (HIV).
19. Previous history of active Hepatitis B (e.g., HBsAg reactive), Hepatitis C, Active
20. Have received a live vaccine within 4 weeks before the first administration of
21. Hypersensitivity to Pembrolizumab additive.
Contact: Jino Jung, B.S. 82-70-4048-0932 firstname.lastname@example.org
Contact: Jungmin Im, M.S. 82-2-3461-0515 email@example.com
Korea, Republic of
Gachon University Gil Medical Center
Korea, Republic of
Korea, Republic of
Gangnam Severance Hospital
SMT bio Co., Ltd.
Principal Investigator: Seung Woo Park, MD. PhD Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital